Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study
复制标题
DOI：
10.1111/jgs.17153
复制
发表时间：
2021-04-02
影响因子：
6.3
通讯作者：
Abizanda, Pedro
中科院分区：
文献类型：
--
作者：
Salmeron Rios, Sergio;Mas Romero, Marta;Abizanda, Pedro
背景/目的BNT162b2冠状病毒病2019 （COVID-19）疫苗在不同虚弱和残疾状况的老年人中的安全性和免疫原性尚未得到很好的确定。我们的目的是分析BNT162b2 mRNA COVID-19疫苗在不同虚弱和残疾状况的老年人中的免疫原性。设计多中心纵向队列研究。背景和参与者在西班牙阿尔巴塞特的五家长期护理机构（ltcf）中，共有134名年龄在bb0 = 65岁的不同虚弱和残疾状况的居民。干预和测量根据标签给居民注射两剂疫苗，在第一次和第二次接种后21.9天（SD 9.3）测定抗体水平。使用日常生活活动（Barthel指数）评估功能变量，并使用虚弱仪器确定虚弱状态。同时评估认知状况和合并症。结果平均年龄82.9岁（65 ~ 99岁），女性占71.6%。既往感染和未感染的居民的平均抗体滴度分别为49,878 AU/ml和15,274 AU/ml（平均差值为34604；95%可信区间[CI]: 27,699-41,509）。两剂疫苗接种后均未观察到严重不良反应。接种COVID-19疫苗后抗体水平升高（B = 31,337; 95% CI: 22,725-39,950; p < 0.001）。虚弱、残疾、年龄较大、性别、认知障碍或合并症与不同抗体滴度无关。结论BNT162b2 mRNA新冠病毒疫苗在老年人中是安全的，具有免疫原性，与虚弱和残疾情况无关。ltcf中的老年人应接种COVID-19疫苗。
Background/Objectives The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles.Design Multicenter longitudinal cohort study.Setting and participants A total of 134 residents aged >= 65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain.Intervention and measurements Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated.Results Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19 infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers.Conclusions The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine.